Common Pregnancy Medications Linked to Increased Autism Risk in Children, Study Finds
A groundbreaking study examining more than six million maternal-child health records has revealed that common prescription medications taken during pregnancy may significantly increase a child's risk of developing autism spectrum disorder. The research, conducted by scientists at the University of Nebraska Medical Center, represents one of the most comprehensive investigations into medication-related autism risk factors to date.
Cholesterol-Inhibiting Drugs Under Scrutiny
The study focused specifically on sterol biosynthesis-inhibiting medications (SBIMs), a category of drugs that includes widely prescribed antidepressants, beta blockers for anxiety and high blood pressure, and cholesterol-lowering statins. These medications work by disrupting the body's natural cholesterol production pathways, which researchers believe may have unintended consequences for fetal brain development.
"Our findings do not suggest that these medications are unsafe for adults," emphasized Dr. Karoly Mirnics, senior study author and dean of the UNMC Munroe–Meyer Institute. "But they raise important questions about their use during pregnancy, a period when even small biochemical disruptions may have outsized effects on fetal brain development."
Alarming Risk Increases Revealed
The research team analyzed 6.14 million health records from the Epic Cosmos database, representing nearly one-third of all U.S. births between 2014 and 2023. Their findings revealed several concerning patterns:
- Mothers prescribed at least one SBIM during pregnancy had a 1.5-fold increased chance of having an autistic child
- For each additional SBIM prescribed, the risk increased an additional 1.3 times
- Women taking four or more SBIMs during pregnancy showed a 2.3-fold increased risk
- Of the 196,447 children diagnosed with autism in the study, 14.2 percent had prenatal exposure to SBIMs
- Use of SBIMs during pregnancy increased dramatically from 4.3 percent in 2014 to 16.8 percent in 2023
The Cholesterol Connection to Brain Development
The study's findings are particularly significant because cholesterol plays a crucial role in brain development. Approximately 20 percent of the body's total cholesterol resides in the brain, where it creates synapses (connections between neurons) and forms protective cell membranes. Many children with autism spectrum disorder have been found to have low cholesterol levels, suggesting disruptions in their brains' communication networks.
This connection is further supported by research on Smith-Lemli-Opitz syndrome (SLOS), a genetic disorder affecting one in 20,000 U.S. births that disrupts the brain's cholesterol-producing pathway. Remarkably, 75 percent of children with SLOS also meet the criteria for autism spectrum disorder.
Common Medications Included in the Study
The researchers evaluated prescriptions for 14 different SBIMs that collectively account for approximately 400 million yearly prescriptions in the United States. The medications studied included:
- Antipsychotics: aripiprazole (Abilify) and haloperidol (Haldol)
- Anxiety medication: buspirone (BuSpar)
- Antidepressants: bupropion (Wellbutrin), fluoxetine (Prozac), sertraline (Zoloft), and trazodone
- Beta blockers: metoprolol, propranolol, and nebivolol
- Statins: atorvastatin (Lipitor), pravastatin, rosuvastatin (Crestor), and simvastatin (Zocor)
Important Medical Guidance for Pregnant Women
The study authors have issued crucial guidance for pregnant women and their healthcare providers. They strongly urge pregnant women not to stop any prescribed medications abruptly without medical supervision, as discontinuing drugs such as antidepressants and beta blockers can lead to serious withdrawal symptoms including fever, chills, severe anxiety, and heart palpitations.
Instead, the researchers recommend that doctors treating pregnant patients carefully evaluate all medications that could have sterol-inhibiting effects and consider safer alternatives when possible. This approach balances the need to manage maternal health conditions with minimizing potential risks to fetal development.
The study, published in the prestigious journal Molecular Psychiatry, comes at a time when autism now affects one in 31 American children—a dramatic increase from one in 150 in the early 2000s. While experts continue to investigate multiple potential causes ranging from improved diagnostic criteria to environmental factors, this research provides important new evidence about medication-related risks during pregnancy.
